PubMed HealthSearch

PubMed · 9452779

[Transdermal therapeutic methods].

Abstract

Percutaneous absorption has now been largely demonstrated and is defined as the passage of a molecule applied to the skin from the external environment to the blood. This phenomenon takes place in two main steps: penetration and actual absorption. Percutaneous absorption avoids the first-pass effect to which orally and rectally administered molecules are submitted, although these molecules can be metabolized in the skin, but to a much lesser degree that by hepatic metabolism. Transdermal devices present many advantage compared to forms administered by other routes: improved patient compliance, easy self-administration, prolonged plasma plateau levels. However, it depends on the skin type and, in the case of allergic reactions, other classical forms designed for the cutaneous route, such as ointments or gels. There are two types of transdermal device: so-called matricial forms, which are semi-solid or solid preparations in which the active ingredient(s) can be dispersed or dissolved; reservoir systems, in which one of the walls is a membrane, placed directly on the skin. In the case of the nitroglycerin, plasma curves are essentially identical regardless of the type of device used. The active ingredients currently available on the market in the form of transdermal devices are scopolamine, nitroglycerin, 17-beta-oestradiol, nicotine, and, for the future, forms containing fentanyl, timolol, ephedrine ... are currently being developed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J M Aiache. [Transdermal therapeutic methods].. https://pubmed.ncbi.nlm.nih.gov/9452779/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption.

The purpose of this study was to determine the plasma concentrations of selected NSAIDs after topical gel administration and to determine the influence of the physicochemical characteristics of these drugs on transdermal absorption. Plasma concentrations of the drugs were determined using high performance liquid chromatography. The logP values obtained from literature for piroxicam, ketoprofen, naproxen, ibuprofen and indomethacin, (1.8, 0.97, 3.22, 3.6 and 3.8, respectively) correlated with the area under the plasma-time curve (AUC) values. The AUC values determined were 527.00 (piroxicam) 269. 45 (ketoprofen) 258.65 (naproxen) 243.22 (indomethacin) and 88.09 (ibuprofen) microg/ml per h. It was concluded that the most reliable parameter for transdermal absorption was the lipophilic character of a drug (logP value). The molecular mass, solubility constraint and percentage unionized moiety can only be used in combination with other properties in the prediction of possible transdermal drug delivery.

Administration, Cutaneous

Pulsed release of nitroglycerin from transdermal drug delivery systems.

To achieve a discontinuous drug delivery to the skin a new actively controlled transdermal system has been developed. The system consists of a tube shaped drug reservoir in combination with an electronic circuit and a gas producing cell. A magnetic switch was used to control the onset of the production of hydrogen gas. The gas was generated with a constant rate. The tube reservoir was filled with a solution of nitroglycerin in propylene glycol. A discontinuous distribution of nitroglycerin in the reservoir is responsible for the pulsed release. 2, 3, 4, or 6 fractions of nitroglycerin solution, which were separated from each other by sections with air, were filled into the tube reservoir. The release studies show that the release patterns directly reflect the number of doses, which were filled into the tube. A lag time of about 60 min was obtained, if the gas production is regulated by a 2.7 kOmega resistor. The drug is released during the pre-programmed time intervals within 6-7 h. Between the time intervals no drug release occurs.

Administration, Cutaneous